Combination Facial Aesthetic Treatment in Millennials.

BACKGROUND: There is growing demand for minimally invasive cosmetic procedures in the millennial population, with botulinum toxin and dermal fillers among the most popular products. OBJECTIVE: To evaluate patient satisfaction and psychosocial impact of multimodal aesthetic treatment in a millennial cohort. METHODS AND MATERIALS: In this single-center, prospective, rater-blinded, pilot study, 20 millennial participants received a samevisit combination facial aesthetic treatment using botulinum toxin and dermal fillers, with an optional botulinum toxin touch-up at 2 weeks. Assessments were conducted at baseline and 2 months post-treatment. The primary endpoint was change in satisfaction with overall facial appearance post-treatment. Secondary endpoints included changes in satisfaction with various facial areas, social and psychosocial functioning, self-perceived age, and blinded clinician assessment. RESULTS: Participants reported significantly greater satisfaction with overall facial appearance 2 months post-treatment when compared to pre-treatment (P<0.001). Participants self-reported numerous improvements in appearance, including greater satisfaction with various properties of the lips, cheeks, and overall facial lines, self-perceived age, and social and psychological functioning. CONCLUSION: Combination botulinum toxin and dermal filler treatment is a safe and effective means of improving millennial satisfaction with overall facial appearance and various facial areas, decreasing self-perceived age, and improving aspects of psychosocial functioning. J Drugs Dermatol. 2022;21(1)37-42. doi:10.36849/JDD.6425.

Medical management of recurrent endometrioma with long-term norethindrone acetate.

PURPOSE: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma. PATIENTS AND METHODS: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment. RESULTS: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months. CONCLUSION: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.